A guide for travel vaccines - compiled by Jane Chiodini

Always use this table in conjunction with information from the SmPC at www.medicines.org.uk the BNF at www.medicines.org.uk the SNF at www.medicines.org.uk the <a href="www

VACCINE NAME		AGE GROUPS	WHEN TO BOOST- general principles and comments		
HEPATITIS A vaccine (and schedules)					
• Hep A vaccine SmPCs have different timings - note Ch. 4, 1 paragraph in GB Ideally, follow the summary of product					
VAQTA® Paediatric	2 dose schedule of	1-17 years	characteristics but in late - presenting		
VAQTA® Adult	hepatitis. A vaccine should be given at day 0 and then 6 to 12 months after the initial dose as recommended in Green Book for hep A vaccines.	18 years and over	travellers, a course does not need to be restarted. Protection is expected for 25 years from the second dose, then a further booster is generally not needed, except for those at ongoing		
Avaxim®		16 years and over			
Avaxim® Junior		1-15 years			
Havrix Junior		1-15 years			
Monodose®		1-13 years			
Havrix Monodose®		16 years and over	risk (<u>UKHSA 2022</u>). Also see NaTHNaC		
	Regimes may vary in SmPCs, see above • & key	,	& info on Hepatitis A ** plus detail		
	Silires, see above • & key		below within the ' Key ' section regarding		
TVDLIOID vessins			GSK 'Havrix' vaccines***.		
TYPHOID vaccine		2 years and over	2 110000		
Typhim Vi® Single dos	se	2 years and over (but see GB for off-	3 years		
		license use from 12mths)			
Vivotif® (Ty21a) Oral	vaccine on days 0, 2 & 4	5 years and over	3 years (Take with cold or luke warm drink 1		
, , , : ::: ::: ::: ::: ; = :: :		,	hr before meal, swallow capsule whole)		
HEPATITIS B vaccine (and schedules) Important – Hep B now in the childhood programme not included here					
Engerix B [®] - 0, 1 and	6 months	Over 16 years	Note: 0, 1, 2 month schedule - Green Book		
Engerix B ® - 0, 1, 2 an	nd 12 months	Over 16 years	now advises a 4 th dose at 12 months in		
Engerix B ® - 0, 7, 21 c	days & 12 months	Over 18 years in SmPC –	the 2024 edition, see Ch.18 pages 16/17. Green Book policy for hepatitis B for all who have received a primary course (which		
		But also 16 -18 years in			
Engaria De Dondistrio	0 1 C months	Green Book			
Engerix B® Paediatric 0, 1, 6 months		0 to 15 years 0 to 15 years	would include travellers) also children vaccinated according to the routine childhood schedule and individuals at high		
Engerix B® Paediatric 0, 1, 2 and 12 months		·			
Engerix B® Option of two doses of 1 ml (20mcg)		11 – 15 years			
for low-compliance adolescents given 6 months apart when the risk of hepatitis B is low and			risk of exposure do not require a reinforcing		
completion of course can be assured before risk			dose of hep B containing vaccine. This		
is high			advice now includes healthcare workers (certain groups not included i.e. people with kidney failure, at the time of a significant exposure & healthcare and laboratory workers who have not responded to the		
HBvaxPRO® 0, 1, and 6 months		16 years and over			
HBvaxPRO ® 0, 1, 2 and 12 months		16 years and over			
	HBvaxPRO ® Paediatric 0, 1 & 6 months				
	0, 1, 2 and 12 months	0 – 15 years 0 – 15 years	primary course). Read Ch. 18, page 17 in GB		
		<u>, </u>			
PreHevBri® ▼ 0, 1, an	nd 6 months	18 years and over	Use may be preferable in those likely to have		
		10	a poorer response – see page 16/17 in the Green Book and be sure to read all the details		
Heplisav B® ▼ 0 and 1	montn	18 years and over	on these newer vaccines		
COMBINED vaccine	es (and schedules)		on these newer vaccines		
		16 years and over	See information about hepatitis A and		
Twinrix Adult® (Hepatitis A and B) 0, 1, 6 months Twinrix Adult® 0, 7, 21, days and 12 months		18 years and over	hepatitis B regarding boosters above. Twinrix		
Twinrix Addit* 0, 7, 2 Twinrix Paediatric® 0	• •	1 – 15 years	Adult rapid schedule could be given from 16		
	•	1 – 15 years	yrs where rapid protection required – see GB		
Ambirix® (Hepatitis A and B) 0 & 6-12 months		•	page 16, but also <u>national PGD</u> from UKHSA		
Discontinued combined Hep A & Typhoid – important to be aware of incase these vaccines are documented in records.					
These were Hepatyrix and VIATIM® used only for adults. Both contained an adult dose of hepatitis A and a dose of typhoid.					
Tetanus, polio & low dose diphtheria (for travel purposes)					
	k at destination and UK	From 6 years - for	10 years if risk at destination and risk of		
schedule completed more than 10 years ago –		travel purposes expect	immunoglobulin not being available		
see Green Book p372		to give older than this			
			<u>l</u>		

MENINGOCOCCAL vaccine	AGE GROUPS	WHEN TO BOOST		
Menveo® Single dose (conjugate vaccine)	2 years	5-yearly for Hajj, Umrah certificate purposes as		
Nimenrix Single dose (conjugate vaccine) MenQuadfi Single dose (conjugate vaccine)	6 weeks of age 12 months of age and older	per KSA in 2017 ⁺ For travel, boost every 5 yrs until more data available. See NaTHNaC at reinforcing immunisation https://goo.gl/6eSWmu N.B. Children under 1 year need different dosing – see Green Book and NaTHNaC & note SmPC differs		
RABIES vaccine 2.5IU; one vial (and schedules)				
Rabipur® 0, 7, 21 or 28 days Accelerated primary course given IM on days0, 3, 7 and 365 when there is insufficient time to complete the 0, 7, 21-28 day course. Note: Rabies Vaccine BP made by Sanofi Pasteur was discontinued in 2022.	Any age but careful risk assessment under 1 year	Many travellers may not need a booster but one single booster dose of vaccine can be considered following thorough risk assessment, in those who completed a primary course over a year ago. This may be most effective if offered 5 years of more after the primary course if travel is assessed as high risk. See Vaccine Update page 5 in issue 282.		
YELLOW FEVER vaccine				
Stamaril® Single dose	Over 9 months	Lifelong in most. See resources for latest details. Certificate valid 10 days post vaccination		
CHOLERA vaccine				
Dukoral® Oral vaccine. 2 doses, minimum 1 wk. and maximum 6 weeks apart, given to those from 6yrs of age. 3 doses given in those 2 – 6 yrs old	2 years and over	6 months when given to those aged 2 – 6 yrs 2 yrs in those aged 6 yrs to adult age NBM 1 hr before & after vaccine		
JAPANESE ENCEPHALITIS vaccine				
IXIARO® 0 and 28 days for all age groups. 0.5ml dose for adults & 3 yr to < 18 yr age group 0.25ml for 2 months to < 3yr age group (See SPC for specific instructions) Note: SPC & GB change for new 0 & 7 days schedule in 18-64 yrs & off license in children from 2 months and over 65 yrs when genuinely no time to complete standard schedule	From 2 months	1 year if at continuous/further risk All others, boost at 12-24 months but see GB for those 65 years and older. Second booster in 18-64 years offer at 10 years. Please see GB for children and those over 65 years for more specific information. Note: primary immunisation should ideally be completed at least one wk prior to JEV exposure		
TICK BORNE ENCEPHALITIS vaccine				
Tico-Vac® 3 doses of 0.5ml on day 0, 1-3 months after 1 st dose, 5-12 months after 2 nd dose For rapid short-term protection – 2 nd dose can be given 2 weeks after 1 st dose – see 'Green Book' Tico-Vac® Junior (0.25ml) 3 doses – same dosing	16 years and over 1 year to below 16	Booster at 3 years after initial 3 dose course is completed if individual continues to be at risk. After this, boosters can be given every 5 years but in those aged > 60 years, booster intervals should not exceed three years		
schedule as adult Tico-Vac®	years of age			

KEY

- + KSA = Kingdom of Saudi Arabia guidance, see NaTHNaC Hajj and Umrah (travelhealthpro.org.uk)
- * Within the Summary of Product Characteristics (SmPC)
- ** The Green Book (2022) refers to all hepatitis A products, so the 25 year protection also applies to the combined products and paediatric hepatitis A vaccines. Until further evidence is available on persistence of protective immunity, a further booster at 25 years is generally not needed except for those at ongoing risk. See the Green Book chapter (page 9) and NaTHNaC document at https://travelhealthpro.org.uk/factsheet/21/hepatitis-a
- ***SmPCs for Havrix Monodose & Havrix Junior Monodose (2022) and Avaxim Junior (2023) states 'Current data do not support the need for further booster vaccination among immune-competent subjects after 2 dose vaccination course' but we continue to follow UKHSA guidance as previously described, even in this situation.

▼Black triangle scheme - drug subject to additional monitoring - see here

Sources of Information for this chart taken from:

UK Health Security Agency (2021) Immunisation Against Infectious Diseases – The Green Book with subsequent updates and revised chapters found on this website. lmmunisation against infectious disease - GOV.UK (www.gov.uk)
Electronic Medicines Compendium www.medicines.org.uk/emc/ www.travelhealthpro.org.uk and www.travax.nhs.uk
IMPORTANT — Where there is a difference between the GB and the SPC, the GB should followed Ch 4. Page 25